Skip to main content

Articles

Page 1 of 98

  1. The breast cancer genome dynamically evolves during malignant progression and recurrence. We investigated the genomic profiles of primary early-stage breast cancers and matched relapses to elucidate the molecu...

    Authors: Caterina Fumagalli, Alberto Ranghiero, Sara Gandini, Federica Corso, Sergio Taormina, Elisa De Camilli, Alessandra Rappa, Davide Vacirca, Giuseppe Viale, Elena Guerini-Rocco and Massimo Barberis

    Citation: Breast Cancer Research 2020 22:107

    Content type: Research article

    Published on:

  2. Breast cancer survivors (BCS) may have increased risk of hypothyroidism, but risk according to treatment modality is unclear. We estimated the incidence of hypothyroidism in women with breast cancer, and accor...

    Authors: Anne Mette Falstie-Jensen, Buket Ö. Esen, Anders Kjærsgaard, Ebbe L. Lorenzen, Jeanette D. Jensen, Kristin V. Reinertsen, Olaf M. Dekkers, Marianne Ewertz and Deirdre P. Cronin-Fenton

    Citation: Breast Cancer Research 2020 22:106

    Content type: Research article

    Published on:

  3. ErbB2/HER2 oncoprotein often drives breast cancers (BCs) which are treated with the anti-ErbB2 antibody trastuzumab. The efficacy of trastuzumab-based metastatic BC therapies is routinely assessed by imaging s...

    Authors: Arik Durcker, Byong Hoon Yoo, Iman Aftab Khan, Dongsic Choi, Laura Montermini, Xiaoyang Liu, Sanja Jovanovic, Tallal Younis and Kirill V. Rosen

    Citation: Breast Cancer Research 2020 22:105

    Content type: Research article

    Published on:

  4. Systemic inflammation may play a role in shaping breast composition, one of the strongest risk factors for breast cancer. Pubertal development presents a critical window of breast tissue susceptibility to exog...

    Authors: Karin B. Michels, Kristen Keller, Ana Pereira, Claire E. Kim, José L. Santos, John Shepherd, Camila Corvalan and Alexandra M. Binder

    Citation: Breast Cancer Research 2020 22:104

    Content type: Research article

    Published on:

  5. Sunitinib, a receptor tyrosine kinase (RTK) inhibitor that targets multiple receptors such as vascular endothelial growth factor receptors (VEGFRs), was approved for cancer treatment in 2006. However, it was u...

    Authors: Denian Wang, Fei Xiao, Zhongxue Feng, Min Li, Lingmiao Kong, Luping Huang, Yong’gang Wei, Hongyu Li, Fei Liu, Haili Zhang and Wei Zhang

    Citation: Breast Cancer Research 2020 22:103

    Content type: Research article

    Published on:

  6. Breast cancer arises within specific regions in the human breast referred to as the terminal duct lobular units (TDLUs). These are relatively dynamic structures characterized by sex hormone driven cyclic epith...

    Authors: Mikkel Morsing, Jiyoung Kim, René Villadsen, Nadine Goldhammer, Abbas Jafari, Moustapha Kassem, Ole William Petersen and Lone Rønnov-Jessen

    Citation: Breast Cancer Research 2020 22:102

    Content type: Research article

    Published on:

  7. A decrease in breast density due to tamoxifen preventive therapy might indicate greater benefit from the drug. It is not known whether mammographic density continues to decline after 1 year of therapy, or whet...

    Authors: Adam R. Brentnall, Ruth Warren, Elaine F. Harkness, Susan M. Astley, Julia Wiseman, Jill Fox, Lynne Fox, Mikael Eriksson, Per Hall, Jack Cuzick, D. Gareth Evans and Anthony Howell

    Citation: Breast Cancer Research 2020 22:101

    Content type: Research article

    Published on:

  8. Exposure to certain outdoor air pollutants may be associated with a higher risk of breast cancer, though potential underlying mechanisms are poorly understood. We examined whether outdoor air pollution was ass...

    Authors: Nicole M. Niehoff, Alexander P. Keil, Rena R. Jones, Shaoqi Fan, Gretchen L. Gierach and Alexandra J. White

    Citation: Breast Cancer Research 2020 22:100

    Content type: Research article

    Published on:

  9. Well-tolerated and commonly used medications are increasingly assessed for reducing breast cancer risk. These include metformin and statins, both linked to reduced hormone availability and cell proliferation o...

    Authors: Erica J. Lee Argov, Teofilia Acheampong, Mary Beth Terry, Carmen B. Rodriguez, Mariangela Agovino, Ying Wei, Shweta Athilat and Parisa Tehranifar

    Citation: Breast Cancer Research 2020 22:99

    Content type: Research article

    Published on:

  10. Previous cohort studies have reported plasma TK1 activity (pTKa) as a potential prognostic biomarker in estrogen receptor-positive (ER+) HER2-negative (HER2−) metastatic breast cancer (MBC). In this prospectiv...

    Authors: Luc Cabel, Dan Rosenblum, Florence Lerebours, Etienne Brain, Delphine Loirat, Mattias Bergqvist, Paul Cottu, Anne Donnadieu, Anne Bethune, Nicolas Kiavue, Manuel Rodrigues, Jean-Yves Pierga, Marie-Laure Tanguy and François-Clément Bidard

    Citation: Breast Cancer Research 2020 22:98

    Content type: Research article

    Published on:

  11. Elacestrant is an oral selective estrogen receptor (ER) degrader. This phase 1b open-label, non-randomized study (RAD1901-106) was initiated to determine the effect of elacestrant on the availability of ER in ...

    Authors: Agnes Jager, Elisabeth G. E. de Vries, C. Willemien Menke-van der Houven van Oordt, Patrick Neven, Clasina M. Venema, Andor W. J. M. Glaudemans, Yamei Wang, Rebecca G. Bagley, Maureen G. Conlan and Philippe Aftimos

    Citation: Breast Cancer Research 2020 22:97

    Content type: Research article

    Published on:

  12. Use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) has been hypothesized to be associated with reduced risk of breast cancer; however, results of epidemiological studies have been mixed. F...

    Authors: Kimberly A. Bertrand, Traci N. Bethea, Hanna Gerlovin, Patricia F. Coogan, Lauren Barber, Lynn Rosenberg and Julie R. Palmer

    Citation: Breast Cancer Research 2020 22:96

    Content type: Research article

    Published on:

  13. Mammographic density (MD) is a strong risk factor for breast cancer. We examined how endogenous plasma hormones are associated with average MD area (cm2) and annual MD change (cm2/year).

    Authors: Marike Gabrielson, Shadi Azam, Elina Hardell, Madeleine Holm, Kumari A. Ubhayasekera, Mikael Eriksson, Magnus Bäcklund, Jonas Bergquist, Kamila Czene and Per Hall

    Citation: Breast Cancer Research 2020 22:95

    Content type: Research article

    Published on:

  14. Obesity and low muscle mass are associated with worse outcomes of breast cancer patients. We conducted a controlled trial to study the impact of a ketogenic diet (KD) based on natural foods versus an unspecifi...

    Authors: Rainer J. Klement, Colin E. Champ, Ulrike Kämmerer, Petra S. Koebrunner, Kelley Krage, Gabriele Schäfer, M. Weigel and Reinhart A. Sweeney

    Citation: Breast Cancer Research 2020 22:94

    Content type: Research article

    Published on:

  15. To investigate if baseline and/or changes in contralateral background parenchymal enhancement (BPE) and fibroglandular tissue (FGT) measured on magnetic resonance imaging (MRI) and mammographic breast density ...

    Authors: Roberto Lo Gullo, Isaac Daimiel, Carolina Rossi Saccarelli, Almir Bitencourt, Varadan Sevilimedu, Danny F. Martinez, Maxine S. Jochelson, Elizabeth A. Morris, Jeffrey S. Reiner and Katja Pinker

    Citation: Breast Cancer Research 2020 22:93

    Content type: Research article

    Published on:

  16. Metaplastic breast carcinoma (MBC) is a rare histological type of breast cancer, which commonly shows resistance to standard therapies and is associated with poor prognosis. The immune microenvironment in MBC ...

    Authors: Xue Chao, Lili Liu, Peng Sun, Xia Yang, Mei Li, Rongzhen Luo, Yuhua Huang, Jiehua He and Jingping Yun

    Citation: Breast Cancer Research 2020 22:92

    Content type: Research article

    Published on:

  17. Metastatic breast cancer remains incurable. Next-generation sequencing (NGS) offers the ability to identify actionable genomic alterations in tumours which may then be matched with targeted therapies, but the ...

    Authors: Courtney T. van Geelen, Peter Savas, Zhi Ling Teo, Stephen J. Luen, Chen-Fang Weng, Yi-An Ko, Keilly S. Kuykhoven, Franco Caramia, Roberto Salgado, Prudence A. Francis, Sarah-Jane Dawson, Stephen B. Fox, Andrew Fellowes and Sherene Loi

    Citation: Breast Cancer Research 2020 22:91

    Content type: Research article

    Published on:

  18. The Oncotype DX 21-gene Recurrence Score is a genomic-based algorithm that guides adjuvant chemotherapy treatment decisions for women with early-stage, oestrogen receptor (ER)-positive breast cancer. However, ...

    Authors: Sarah M. Bernhardt, Pallave Dasari, Joseph Wrin, Wendy Raymond, Suzanne Edwards, David Walsh, Amanda R. Townsend, Timothy J. Price and Wendy V. Ingman

    Citation: Breast Cancer Research 2020 22:90

    Content type: Research article

    Published on:

  19. Combined targeting of CDK4/6 and ER is now the standard of care for patients with advanced ER+/HER2− breast cancer. However, acquired resistance to these therapies frequently leads to disease progression. As s...

    Authors: Neil A. O’Brien, Martina S. J. McDermott, Dylan Conklin, Tong Luo, Raul Ayala, Suruchi Salgar, Kevin Chau, Emmanuelle DiTomaso, Naveen Babbar, Faye Su, Alex Gaither, Sara A. Hurvitz, Ronald Linnartz, Kristine Rose, Samit Hirawat and Dennis J. Slamon

    Citation: Breast Cancer Research 2020 22:89

    Content type: Research article

    Published on:

  20. Perinatal factors have been associated with some adult health outcomes, but have not been well studied in young-onset breast cancer. We aimed to evaluate the association between young-onset breast cancer and peri...

    Authors: Mary V. Diaz-Santana, Katie M. O’Brien, Aimee A. D’Aloisio, Gloria Regalado, Dale P. Sandler and Clarice R. Weinberg

    Citation: Breast Cancer Research 2020 22:88

    Content type: Research article

    Published on:

  21. Resistance to endocrine therapy is a major clinical challenge in the management of oestrogen receptor (ER)-positive breast cancer. In this setting, p53 is frequently wildtype and its activity may be suppressed...

    Authors: Neil Portman, Heloisa H. Milioli, Sarah Alexandrou, Rhiannon Coulson, Aliza Yong, Kristine J. Fernandez, Kee Ming Chia, Ensar Halilovic, Davendra Segara, Andrew Parker, Sue Haupt, Ygal Haupt, Wayne D. Tilley, Alex Swarbrick, C. Elizabeth Caldon and Elgene Lim

    Citation: Breast Cancer Research 2020 22:87

    Content type: Research article

    Published on:

  22. Tumor-derived extracellular vesicles (tdEVs) and circulating tumor cells (CTCs) in the blood of metastatic cancer patients associate with poor outcomes. In this study, we explored the human epidermal growth fa...

    Authors: Afroditi Nanou, Leonie Laura Zeune, Francois-Clement Bidard, Jean-Yves Pierga and Leonardus Wendelinus Mathias Marie Terstappen

    Citation: Breast Cancer Research 2020 22:86

    Content type: Research article

    Published on:

  23. Invasive lobular carcinoma (ILC) accounts for 10–15% of primary breast cancers and is typically estrogen receptor alpha positive (ER+) and ERBB2 non-amplified. Somatic mutations in ERBB2/3 are emerging as a tract...

    Authors: Sasagu Kurozumi, Mansour Alsaleem, Cíntia J. Monteiro, Kartikeya Bhardwaj, Stacey E. P. Joosten, Takaaki Fujii, Ken Shirabe, Andrew R. Green, Ian O. Ellis, Emad A. Rakha, Nigel P. Mongan, David M. Heery, Wilbert Zwart, Steffi Oesterreich and Simon J. Johnston

    Citation: Breast Cancer Research 2020 22:85

    Content type: Research article

    Published on:

  24. Endocrine therapy is the most common treatment for estrogen receptor (ER)-positive breast cancer, but its effectiveness is limited by high rates of primary and acquired resistance. There are likely many geneti...

    Authors: Li Li, Ling Lin, Jamunarani Veeraraghavan, Yiheng Hu, Xian Wang, Sanghoon Lee, Ying Tan, Rachel Schiff and Xiao-Song Wang

    Citation: Breast Cancer Research 2020 22:84

    Content type: Research article

    Published on:

  25. Limited data are available regarding the use of nab-paclitaxel in older patients with breast cancer. A weekly schedule is recommended, but there is a paucity of evidence regarding the optimal dose. We evaluate...

    Authors: Laura Biganzoli, Saverio Cinieri, Rossana Berardi, Rebecca Pedersini, Amelia McCartney, Alessandro Marco Minisini, Elena Rota Caremoli, Simon Spazzapan, Emanuela Magnolfi, Antonella Brunello, Emanuela Risi, Raffaella Palumbo, Silvana Leo, Marco Colleoni, Sara Donati, Sabino De Placido…

    Citation: Breast Cancer Research 2020 22:83

    Content type: Research article

    Published on:

  26. Breast cancer cells invading the connective tissues outside the mammary lobule or duct immerse in a reservoir of extracellular matrix (ECM) that is structurally and biochemically distinct from that of their si...

    Authors: Kelsey F. Ruud, William C. Hiscox, Ilhan Yu, Roland K. Chen and Weimin Li

    Citation: Breast Cancer Research 2020 22:82

    Content type: Research article

    Published on:

  27. Previous studies have identified and validated a risk-associated Active transcriptome phenotype commonly expressed in the cancer-adjacent and histologically normal epithelium, stroma, and adipose containing perit...

    Authors: Taekyu Kang, Christina Yau, Christopher K. Wong, John Z. Sanborn, Yulia Newton, Charlie Vaske, Stephen C. Benz, Gregor Krings, Roman Camarda, Jill E. Henry, Josh Stuart, Mark Powell and Christopher C. Benz

    Citation: Breast Cancer Research 2020 22:81

    Content type: Research article

    Published on:

  28. The estrogen receptor (ER)-positive breast cancer represents over 80% of all breast cancer cases. Even though adjuvant hormone therapy with tamoxifen (TMX) is saving lives of patients with ER-positive breast c...

    Authors: Madhurendra Singh, Xiaolei Zhou, Xinsong Chen, Gema Sanz Santos, Sylvain Peuget, Qing Cheng, Ali Rihani, Elias S. J. Arnér, Johan Hartman and Galina Selivanova

    Citation: Breast Cancer Research 2020 22:80

    Content type: Research article

    Published on:

  29. We previously showed that BRCA-like profiles can be used to preselect individuals with the highest risk of carrying BRCA mutations but could also indicate which patients would benefit from double-strand break ind...

    Authors: Esther H. Lips, Anne Benard-Slagter, Mark Opdam, Caroline E. Scheerman, Jelle Wesseling, Frans B. L. Hogervorst, Sabine C. Linn, Suvi Savola and Petra M. Nederlof

    Citation: Breast Cancer Research 2020 22:79

    Content type: Research article

    Published on:

  30. Previous studies of fatty acids and breast cancer risk have shown mixed results, which may be due in part to tumor heterogeneity. Prior research has also illustrated an important role of specific fatty acids i...

    Authors: Emma E. McGee, Claire H. Kim, Molin Wang, Donna Spiegelman, Daniel G. Stover, Yujing J. Heng, Laura C. Collins, Gabrielle M. Baker, Maryam S. Farvid, Pepper Schedin, Sonali Jindal, Rulla M. Tamimi and A. Heather Eliassen

    Citation: Breast Cancer Research 2020 22:78

    Content type: Research article

    Published on:

  31. For patients with locally advanced estrogen receptor or progesterone receptor-positive breast cancer, neoadjuvant endocrine therapy (NET) facilitates down-staging of the tumor and increased rates of breast-con...

    Authors: Lauren I. Madigan, Phuong Dinh and J. Dinny Graham

    Citation: Breast Cancer Research 2020 22:77

    Content type: Review

    Published on:

  32. Early luminal breast cancer (BC) represents 70% of newly diagnosed BC cases. Among them, small (under 2 cm) BC without lymph node metastasis (classified as T1N0) have been rarely studied, as their prognosis is...

    Authors: Claire Bonneau, Antoine Eliès, Yann Kieffer, Brigitte Bourachot, Sylvain Ladoire, Floriane Pelon, Delphine Hequet, Jean-Marc Guinebretière, Christophe Blanchet, Anne Vincent-Salomon, Roman Rouzier and Fatima Mechta-Grigoriou

    Citation: Breast Cancer Research 2020 22:76

    Content type: Research article

    Published on:

  33. PGRMC1 (progesterone receptor membrane component 1) is a highly conserved heme binding protein, which is overexpressed especially in hormone receptor-positive breast cancer and plays an important role in breas...

    Authors: Hannah Asperger, Nadia Stamm, Berthold Gierke, Michael Pawlak, Ute Hofmann, Ulrich M. Zanger, Annamaria Marton, Robert L. Katona, Andrea Buhala, Csaba Vizler, Jan-Philipp Cieslik, Eugen Ruckhäberle, Dieter Niederacher, Tanja Fehm, Hans Neubauer and Marina Ludescher

    Citation: Breast Cancer Research 2020 22:75

    Content type: Research article

    Published on:

  34. Cancer cells are known to display varying degrees of metastatic propensity, but the molecular basis underlying such heterogeneity remains unclear. Our aims in this study were to (i) elucidate prognostic subtyp...

    Authors: Amin Emad, Tania Ray, Tor W. Jensen, Meera Parat, Rachael Natrajan, Saurabh Sinha and Partha S. Ray

    Citation: Breast Cancer Research 2020 22:74

    Content type: Research article

    Published on:

  35. Studies on tumor-secreted microRNAs point to a functional role of these in cellular communication and reprogramming of the tumor microenvironment. Uptake of tumor-secreted microRNAs by neighboring cells may re...

    Authors: Thilde Terkelsen, Francesco Russo, Pavel Gromov, Vilde Drageset Haakensen, Søren Brunak, Irina Gromova, Anders Krogh and Elena Papaleo

    Citation: Breast Cancer Research 2020 22:73

    Content type: Research article

    Published on:

  36. Breast cancer is the most common malignancy to spread to the orbit and periorbit, and the invasive lobular carcinoma (ILC) histologic subtype of breast cancer has been reported to form these ophthalmic metasta...

    Authors: Martin Blohmer, Li Zhu, Jennifer M. Atkinson, Sushil Beriwal, Joshua L. Rodríguez-López, Margaret Rosenzweig, Adam M. Brufsky, George Tseng, Peter C. Lucas, Adrian V. Lee, Steffi Oesterreich and Rachel C. Jankowitz

    Citation: Breast Cancer Research 2020 22:70

    Content type: Research article

    Published on:

  37. In the evaluation of PD-L1 expression to select patients for anti-PD-1/PD-L1 treatment, uniform guidelines that account for different immunohistochemistry assays, different cell types and different cutoff valu...

    Authors: Hua Guo, Qingqing Ding, Yun Gong, Michael Z. Gilcrease, Min Zhao, Jun Zhao, Dawen Sui, Yun Wu, Hui Chen, Hui Liu, Jinxia Zhang, Erika Resetkova, Stacy L. Moulder, Wei-Lien Wang and Lei Huo

    Citation: Breast Cancer Research 2020 22:69

    Content type: Research article

    Published on:

  38. Breast cancer is a highly heterogeneous disease characterized by multiple histologic and molecular subtypes. While a myriad of breast cancer cell lines have been developed over the past 60 years, estrogen rece...

    Authors: Jessica Finlay-Schultz, Britta M. Jacobsen, Duncan Riley, Kiran V. Paul, Scott Turner, Andrea Ferreira-Gonzalez, J. Chuck Harrell, Peter Kabos and Carol A. Sartorius

    Citation: Breast Cancer Research 2020 22:68

    Content type: Research article

    Published on:

  39. Obesity induces molecular changes that may favor tumor progression and metastatic spread, leading to impaired survival outcomes in breast cancer. Adenylate cyclase-associated protein 1 (CAP1), an actin regulat...

    Authors: Malin Bergqvist, Karin Elebro, Malte Sandsveden, Signe Borgquist and Ann H. Rosendahl

    Citation: Breast Cancer Research 2020 22:67

    Content type: Research article

    Published on:

  40. Triple-negative breast cancer (TNBC) is characterized by high rates of recurrence and poor overall survival. This is due, in part, to a deficiency of targeted therapies, making it essential to identify therape...

    Authors: Melyssa S. Roberts, Lindsey J. Anstine, Viviane S. Finke, Benjamin L. Bryson, Bryan M. Webb, Kristen L. Weber-Bonk, Darcie D. Seachrist, Parth R. Majmudar and Ruth A. Keri

    Citation: Breast Cancer Research 2020 22:66

    Content type: Research article

    Published on:

  41. Crown-like structures in breast adipose tissue (CLS-B), composed of necrotic adipocytes encircled by macrophages, are associated with obesity and hypothesized to worsen breast cancer prognosis; however, data a...

    Authors: Maret L. Maliniak, Aswathy Miriam Cheriyan, Mark E. Sherman, Yuan Liu, Keerthi Gogineni, Jiaqi Liu, Jiabei He, Uma Krishnamurti, Jasmine Miller-Kleinhenz, Ryan Ashiqueali, Jinjing He, Rami Yacoub and Lauren E. McCullough

    Citation: Breast Cancer Research 2020 22:65

    Content type: Research article

    Published on:

  42. Aging is a comorbidity of breast cancer suggesting that aging-associated transcriptome changes may promote breast cancer progression. However, the mechanism underlying the age effect on breast cancer remains p...

    Authors: Xiang Gu, Bingzhi Wang, Haiyan Zhu, You Zhou, Aaron M. Horning, Tim H-M Huang, Yidong Chen, Peter Houghton, Zhao Lai, Joel E. Michalek and Lu-Zhe Sun

    Citation: Breast Cancer Research 2020 22:64

    Content type: Research article

    Published on:

  43. Basal-like breast cancer (BLBC) is a poorly characterised, heterogeneous disease. Patients are diagnosed with aggressive, high-grade tumours and often relapse with chemotherapy resistance. Detailed understandi...

    Authors: Laura A. Baker, Holly Holliday, Daniel Roden, Christoph Krisp, Sunny Z. Wu, Simon Junankar, Aurelien A. Serandour, Hisham Mohammed, Radhika Nair, Geetha Sankaranarayanan, Andrew M. K. Law, Andrea McFarland, Peter T. Simpson, Sunil Lakhani, Eoin Dodson, Christina Selinger…

    Citation: Breast Cancer Research 2020 22:63

    Content type: Research article

    Published on:

  44. African American/Black women with breast cancer have poorer survival than White women, and this disparity persists even after adjusting for non-biological factors. Differences in tumor immune biology have been...

    Authors: Yara Abdou, Kristopher Attwood, Ting-Yuan David Cheng, Song Yao, Elisa V. Bandera, Gary R. Zirpoli, Rochelle Payne Ondracek, Leighton Stein, Wiam Bshara, Thaer Khoury, Christine B. Ambrosone and Angela R. Omilian

    Citation: Breast Cancer Research 2020 22:62

    Content type: Research article

    Published on:

  45. Mitochondrial dynamics underlies malignant transformation, cancer progression, and response to treatment. Current research presents conflicting evidence for functions of mitochondrial fission and fusion in tum...

    Authors: Brock A. Humphries, Alyssa C. Cutter, Johanna M. Buschhaus, Yu-Chih Chen, Tonela Qyli, Dilrukshika S. W. Palagama, Samantha Eckley, Tanner H. Robison, Avinash Bevoor, Benjamin Chiang, Henry R. Haley, Saswat Sahoo, Phillip C. Spinosa, Dylan B. Neale, Jagadish Boppisetti, Debashis Sahoo…

    Citation: Breast Cancer Research 2020 22:60

    Content type: Research article

    Published on:

  46. Breast cancer is a heterogeneous disease. Hence, stratification of patients based on the subtype of breast cancer is key to its successful treatment. Among all the breast cancer subtypes, basal-like breast can...

    Authors: Ritama Paul, Ming Luo, Xueying Mo, Jason Lu, Syn Kok Yeo and Jun-Lin Guan

    Citation: Breast Cancer Research 2020 22:59

    Content type: Research article

    Published on:

    The Correction to this article has been published in Breast Cancer Research 2020 22:71

  47. Ultrafast dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)-derived kinetic parameters have demonstrated at least equivalent accuracy to standard DCE-MRI in differentiating malignant from benign b...

    Authors: Natsuko Onishi, Meredith Sadinski, Mary C. Hughes, Eun Sook Ko, Peter Gibbs, Katherine M. Gallagher, Maggie M. Fung, Theodore J. Hunt, Danny F. Martinez, Amita Shukla-Dave, Elizabeth A. Morris and Elizabeth J. Sutton

    Citation: Breast Cancer Research 2020 22:58

    Content type: Research article

    Published on:

Annual Journal Metrics